Donanemab治疗早期阿尔茨海默病的淀粉样蛋白相关影像学异常:TRAILBLAZER-ALZ与ALZ 2随机临床试验的二次分析
该二次分析基于TRAILBLAZER-ALZ和ALZ 2随机对照试验及开放标签扩展研究,纳入3030例早期症状性阿尔茨海默病患者,评估donanemab相关ARIA的频率、严重程度、症状、时间及危险因素。结果显示donanemab组ARIA-E和ARIA-H频率高于安慰剂组,ARIA-E多为轻中度,严重ARIA-E占1.5%,症状性ARIA-E占5.8%,首次事件多在第三次输注前发生,APOE ε4等基线因素与ARIA-E独立相关。
要点
- donanemab治疗增加ARIA-E和ARIA-H风险,但多为轻中度。
- 首次ARIA-E事件常在第三次输注(约第3个月)前发生。
- APOE ε4状态和基线影像可评估个体ARIA风险。
核心结论
- ARIA是donanemab治疗相关的不良事件,需要安全性监测。
- 个体ARIA风险可通过APOE ε4状态和基线影像学发现进行评估。
研究设计与样本
- 预设和事后探索性分析,使用TRAILBLAZER-ALZ和ALZ 2随机临床试验的安慰剂对照部分数据。
- 纳入两项安慰剂对照试验及开放标签扩展研究,共3030例60至85岁早期症状性阿尔茨海默病且淀粉样蛋白升高患者。
- 安慰剂对照试验按1:1随机分配接受安慰剂或donanemab,开放标签扩展研究所有参与者接受donanemab。
- Donanemab每4周给药一次,最长72周。
主要发现
- 安慰剂对照试验中,donanemab组ARIA-E频率为24.4%,ARIA-H频率为31.3%,安慰剂组分别为1.9%和13.0%。
- 开放标签扩展研究中,donanemab组ARIA-E频率为19.8%,ARIA-H频率为27.2%。
- 安慰剂对照试验中,donanemab治疗者严重ARIA-E报告率为1.5%,症状性ARIA-E为5.8%。
- ARIA-E大多为轻或中度严重程度,最常见症状为头痛和意识模糊状态。
- 58.3%的donanemab治疗者首次ARIA-E事件发生在第三次输注前(约第3个月)。
关键数值与推荐
- ARIA-E与6个基线变量独立相关:APOE ε4等位基因数量增加、微出血数量较多、皮质表面铁沉积、淀粉样斑块较高、平均动脉压升高增加风险,使用降压药降低风险。
临床怎么用
- Donanemab治疗需进行安全性监测以管理ARIA。
- 可利用APOE ε4状态和基线影像学发现评估个体ARIA风险。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Amyloid-related imaging abnormalities (ARIA) are the major adverse event associated with amyloid-targeting immunotherapy. Identifying clinical features and individual risk factors for ARIA could facilitate effective prediction and prevention strategies. OBJECTIVE: To characterize ARIA in participants treated with donanemab. DESIGN, SETTING, AND PARTICIPANTS: These prespecified and post hoc exploratory analyses use data from the placebo-controlled portions of the TRAILBLAZER-ALZ and ALZ 2 randomized clinical trials, conducted from December 2017 to December 2020 and from June 2020 to April 2023, respectively. Additional analyses are included from a stand-alone open-label addendum conducted from August 2021 through August 2023. Participants in the placebo-controlled trials and the open-label addendum aged 60 to 85 years with early symptomatic Alzheimer disease and elevated amyloid levels were included. The placebo-controlled trials, but not the addendum, had tau inclusion criteria. INTERVENTIONS: Placebo-controlled trial participants were randomized 1:1 to receive placebo or donanemab, and all open-label participants received donanemab. Donanemab was administered every 4 weeks for up to 72 weeks. MAIN OUTCOMES AND MEASURES: The primary outcomes were the frequency, radiographic severity, seriousness, symptoms, timing relative to donanemab treatment, and risk factors for ARIA. RESULTS: Across 3030 total participants (placebo-controlled trials: 999 placebo participants, 984 donanemab participants; open-label addendum: 1047 donanemab participants), mean (SD) age was approximately 73.7 (6.0) years and 1684 participants (55.6%) were female. Frequencies of ARIA-edema/effusions (ARIA-E) and ARIA-microhemorrhages and hemosiderin deposition (ARIA-H) were higher with donanemab (24.4% and 31.3% in placebo-controlled trials, respectively; 19.8% and 27.2% in open-label addendum, respectively) than with placebo (1.9% and 13.0%, respectively). ARIA-E was mostly mild or moderate in severity. Serious ARIA-E was reported in 1.5% and symptomatic ARIA-E in 5.8% of donanemab-treated participants in the placebo-controlled trials. Symptoms most frequently reported with ARIA-E were headache and confusional state. In 58.3% of donanemab-treated participants with ARIA-E, the first event occurred by the third infusion (approximately month 3). Risk analysis demonstrated independent associations between ARIA-E and 6 baseline variables, including increased risk with APOE ε4 allele number, greater number of microhemorrhages, presence of cortical superficial siderosis, higher amyloid plaque, and elevated mean arterial pressure, and decreased risk with antihypertensive use. CONCLUSIONS AND RELEVANCE: ARIA is an adverse event associated with donanemab treatment that requires safety monitoring. Individual ARIA risk can be assessed by APOE ε4 status and baseline imaging findings. TRIAL REGISTRATIONS: ClinicalTrials.gov Identifiers: NCT03367403 and NCT04437511.
引用
- Zimmer JA, Ardayfio P, Wang H, et al. Amyloid-Related Imaging Abnormalities With Donanemab in Early Symptomatic Alzheimer Disease: Secondary Analysis of the TRAILBLAZER-ALZ and ALZ 2 Randomized Clinical Trials. JAMA Neurol. 2025. PMID: 40063015. doi:10.1001/jamaneurol.2025.0065
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。